Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 9:54 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–9 of 9 matching trials from the live ClinicalTrials.gov search.
Conditions
Head and Neck Cancer
Interventions
filgrastim, doxorubicin hydrochloride, autologous bone marrow transplantation, peripheral blood stem cell transplantation, indium In 111 monoclonal antibody MN-14, yttrium Y 90 monoclonal antibody MN-14
Biological · Drug · Procedure + 1 more
Lead sponsor
Garden State Cancer Center at the Center for Molecular Medicine and Immunology
Other
Eligibility
16 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2002
U.S. locations
2
States / cities
Belleville, New Jersey • Paterson, New Jersey
Conditions
Colorectal Cancer, Pancreatic Cancer
Interventions
filgrastim, autologous bone marrow transplantation, peripheral blood stem cell transplantation, indium In 111 monoclonal antibody MN-14, yttrium Y 90 monoclonal antibody MN-14
Biological · Procedure · Radiation
Lead sponsor
Garden State Cancer Center at the Center for Molecular Medicine and Immunology
Other
Eligibility
18 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
3
States / cities
Belleville, New Jersey • Paterson, New Jersey • Philadelphia, Pennsylvania
Conditions
Leukemia, Lymphoma
Interventions
filgrastim, autologous bone marrow transplantation, peripheral blood stem cell transplantation, indium In 111 monoclonal antibody MN-14, yttrium Y 90 epratuzumab
Biological · Procedure · Radiation
Lead sponsor
Garden State Cancer Center at the Center for Molecular Medicine and Immunology
Other
Eligibility
18 Years to 80 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
4
States / cities
Belleville, New Jersey • Livingston, New Jersey • Paterson, New Jersey + 1 more
Conditions
Leukemia, Lymphoma
Interventions
filgrastim, cisplatin, cytarabine, etoposide, ifosfamide, autologous bone marrow transplantation, peripheral blood stem cell transplantation, indium In 111 LL2 IgG, yttrium Y 90 epratuzumab
Biological · Drug · Procedure + 1 more
Lead sponsor
Garden State Cancer Center at the Center for Molecular Medicine and Immunology
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
1
States / cities
Belleville, New Jersey
Conditions
Lymphoma, Small Intestine Cancer
Interventions
radionuclide imaging, indium In 111-labeled autologous peripheral blood mononuclear cells, indium In 111-labeled autologous polymorphonuclear leukocytes
Procedure · Radiation
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 120 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2012
U.S. locations
2
States / cities
Iowa City, Iowa • Rochester, Minnesota
Conditions
AIDS-related Peripheral/Systemic Lymphoma, AIDS-related Primary CNS Lymphoma, Post-transplant Lymphoproliferative Disorder, Recurrent Childhood Large Cell Lymphoma, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent Childhood Small Noncleaved Cell Lymphoma, Recurrent/Refractory Childhood Hodgkin Lymphoma
Interventions
rituximab, indium In 111 ibritumomab tiuxetan, yttrium Y 90 ibritumomab tiuxetan, peripheral blood stem cell transplantation, filgrastim, laboratory biomarker analysis
Biological · Radiation · Procedure + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 21 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Arcadia, California
Conditions
Ovarian Cancer
Interventions
filgrastim, peripheral blood stem cell transplantation, indium In 111 monoclonal antibody MN-14, yttrium Y 90 monoclonal antibody MN-14
Biological · Procedure · Radiation
Lead sponsor
Garden State Cancer Center at the Center for Molecular Medicine and Immunology
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
3
States / cities
Belleville, New Jersey • Paterson, New Jersey • Philadelphia, Pennsylvania
Conditions
Glioblastoma
Interventions
Human CMV pp65-LAMP mRNA-pulsed autologous DCs containing GM CSF, Temozolomide, Tetanus-Diphtheria Toxoid (Td), GM-CSF, 111-Indium-labeling of Cells for in vivo Trafficking Studies
Biological · Drug
Lead sponsor
Mustafa Khasraw, MBChB, MD, FRCP, FRACP
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Contiguous Stage II Adult Diffuse Large Cell Lymphoma, Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma, Contiguous Stage II Grade 1 Follicular Lymphoma, Contiguous Stage II Grade 2 Follicular Lymphoma, Contiguous Stage II Grade 3 Follicular Lymphoma, Contiguous Stage II Mantle Cell Lymphoma, Contiguous Stage II Marginal Zone Lymphoma, Contiguous Stage II Small Lymphocytic Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma, Noncontiguous Stage II Grade 1 Follicular Lymphoma, Noncontiguous Stage II Grade 2 Follicular Lymphoma, Noncontiguous Stage II Grade 3 Follicular Lymphoma, Noncontiguous Stage II Mantle Cell Lymphoma, Noncontiguous Stage II Marginal Zone Lymphoma, Noncontiguous Stage II Small Lymphocytic Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Small Lymphocytic Lymphoma, Stage I Adult Diffuse Large Cell Lymphoma, Stage I Adult Diffuse Small Cleaved Cell Lymphoma, Stage I Grade 1 Follicular Lymphoma, Stage I Grade 2 Follicular Lymphoma, Stage I Grade 3 Follicular Lymphoma, Stage I Mantle Cell Lymphoma, Stage I Marginal Zone Lymphoma, Stage I Small Lymphocytic Lymphoma, Stage III Adult Diffuse Large Cell Lymphoma, Stage III Adult Diffuse Small Cleaved Cell Lymphoma, Stage III Grade 1 Follicular Lymphoma, Stage III Grade 2 Follicular Lymphoma, Stage III Grade 3 Follicular Lymphoma, Stage III Mantle Cell Lymphoma, Stage III Marginal Zone Lymphoma, Stage III Small Lymphocytic Lymphoma, Stage IV Adult Diffuse Large Cell Lymphoma, Stage IV Adult Diffuse Small Cleaved Cell Lymphoma, Stage IV Grade 1 Follicular Lymphoma, Stage IV Grade 2 Follicular Lymphoma, Stage IV Grade 3 Follicular Lymphoma, Stage IV Mantle Cell Lymphoma, Stage IV Marginal Zone Lymphoma, Stage IV Small Lymphocytic Lymphoma, Waldenström Macroglobulinemia
Interventions
rituximab, cyclophosphamide, filgrastim, yttrium Y 90 ibritumomab tiuxetan, peripheral blood stem cell transplantation
Biological · Drug · Radiation + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Baltimore, Maryland